We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News Medica 2024 AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Catheter Ablation Superior to Drug Therapy for HF

By HospiMedica International staff writers
Posted on 07 Jan 2019
Catheter ablation is superior to conventional drug therapy alone for patients with atrial fibrillation (AF) and heart failure (HF), according to a new study.

Researchers at Mount Sinai Hospital (New York, NY, USA) conducted a meta-analysis of randomized controlled trials extracted from PubMed, the Cochrane Central Register of Controlled Trials, Google Scholar, and other sources in order to compare clinical outcomes of catheter ablation and drug therapy in adults with AF and HF. Six studies involving 775 patients met the inclusion criteria, and an analysis of the studies revealed that compared to medication, catheter ablation was associated with reductions in all-cause mortality and HF hospitalizations.

In addition, compared with drug therapy, AF ablation improved left ventricular ejection fraction (LVEF) six-minute walk test distance, peak oxygen consumption (VO2max), cardiopulmonary exercise capacity, and overall quality of life. Major adverse events rates were 7.2% in the ablation group and 3.8% in the standard therapy group, but were not statistically significant. The study was published on December 25, 2018, in Annals of Internal Medicine.

“Catheter ablation is an established therapeutic strategy for symptomatic, drug-refractory atrial fibrillation. However, current guidelines support atrial fibrillation ablation with caution,” concluded lead author Mohit Turagam, MD, and colleagues. “The long-term benefits in all-cause mortality, heart failure hospitalizations, and overall clinical outcomes must be weighed in clinical decision making, despite the complications.”

Cardiac catheter ablation is used to treat a variety of cardiac arrhythmias, especially supraventricular tachyarrhythmias such as AF, atrial flutter, and atrial tachycardia. The procedures involve advancing a catheter into the heart and selectively ablating certain areas of tissue to prevent the spread of electrical signals; the procedure is low-risk, usually takes 2-4 hours, and is performed in an electrophysiology or a cardiac catheterization lab. It is successful in about 90% of the people who have it.

Related Links:
Mount Sinai Hospital


Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
New
Ultrasonic Cleaner
Cole-Parmer Ultrasonic Cleaner with Digital Timer
New
Mobile Power Procedure Chair
LeMans P360

Latest Critical Care News

Innovative Ventricular Assist Device Provides Long-Term Support for Advanced Heart Failure Patients

Novel Algorithms Predict Cardiovascular Outcomes at Point-Of-Care Using ECG Data

Novel Medical Device Inventions Use Light to Monitor Blood Pressure and Track Cancer Treatment Progress